IceCure Medical (NASDAQ:ICCM) Shares Down 3.1% – Time to Sell?

Shares of IceCure Medical Ltd (NASDAQ:ICCM) dropped 3.1% during trading on Monday . The stock traded as low as $1.09 and last traded at $1.09. Approximately 107,900 shares changed hands during mid-day trading, a decline of 77% from the average daily volume of 467,094 shares. The stock had previously closed at $1.13.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and set a $2.50 target price on shares of IceCure Medical in a research report on Friday, March 28th.

IceCure Medical Trading Down 3.1 %

The firm has a fifty day moving average of $1.27 and a two-hundred day moving average of $1.06. The company has a market cap of $60.50 million, a PE ratio of -3.76 and a beta of 0.43. The company has a current ratio of 2.67, a quick ratio of 2.27 and a debt-to-equity ratio of 0.02.

IceCure Medical (NASDAQ:ICCM) last posted its earnings results on Thursday, March 27th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.01). IceCure Medical had a negative return on equity of 124.44% and a negative net margin of 376.85%. The business had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $1.07 million. As a group, sell-side analysts predict that IceCure Medical Ltd will post -0.28 EPS for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in IceCure Medical stock. Geode Capital Management LLC raised its stake in IceCure Medical Ltd (NASDAQ:ICCM) by 58.3% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 40,453 shares of the company’s stock after purchasing an additional 14,893 shares during the quarter. Geode Capital Management LLC owned 0.07% of IceCure Medical worth $44,000 at the end of the most recent quarter. Institutional investors own 0.62% of the company’s stock.

IceCure Medical Company Profile

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology.